Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Melanoma Research
Joanna ManganaReinhard Dummer

Abstract

Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients. The current project aims to determine the benefit of the introduction of these new therapies in advanced melanoma across several regions of Switzerland. This is a retrospective multicenter analysis of 395 advanced melanoma patients treated with standard chemotherapy, checkpoint inhibitors, and kinase inhibitors from January 2008 until December 2014. The 1-year survival was 69% (n=121) in patients treated with checkpoint inhibitors (IT), 50% in patients treated with TTs (n=113), 85% in the IT+TT group (n=66), and 38% in patients treated with standard chemotherapy (n=95). The median overall survival (mOS) from first systemic treatment in the entire study cohort was 16.9 months. mOS of patients treated either with checkpoint or kinase inhibitors (n=300, 14.6 months) between 2008 and 2014 was significantly improved (P<0.0001) compared with patients treated with standard chemotherapy in 2008-2009 (n=95, 7.4 months). mOS of 61 patients with brain metastases at stage IV was 8.1 versus 12.5 months for patients without at st...Continue Reading

References

Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K M FifeJ F Thompson
Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Oct 9, 2007·Cancer Treatment Reviews·Philip LuiThomas R Einarson
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
Oct 15, 2010·Expert Opinion on Investigational Drugs·Elisabeth LivingstoneDirk Schadendorf
Oct 21, 2010·Cancer·Michael A DaviesAgop Bedikian
Jun 4, 2011·Biochemical Pharmacology·Inna V FedorenkoKeiran S M Smalley
Jun 7, 2011·JAMA : the Journal of the American Medical Association·Richard D CarvajalGary K Schwartz
Jan 4, 2012·ChemSusChem·Mosaed AlhumaimessGraham J Hutchings
Mar 30, 2012·The Lancet Oncology·Kim MargolinF Stephen Hodi
Oct 13, 2012·Nature Reviews. Drug Discovery·Gideon BollagPeter Hirth
Dec 12, 2012·Expert Opinion on Investigational Drugs·Malgorzata Mackiewicz-WysockaPiotr J Wysocki
Jul 4, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Megan Banaszynski, Jill M Kolesar
Jul 17, 2013·The British Journal of Dermatology·H EkedahlG Jönsson
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick A OttCaroline Robert
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Feb 6, 2015·OncoTargets and Therapy·Francesco SpagnoloPaola Queirolo
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Apr 11, 2015·Melanoma Research·Nadia YousafJames Larkin
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Aug 28, 2015·Expert Review of Anticancer Therapy·Elnaz FaghfuriMohammad Abdollahi
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R DummerUNKNOWN ESMO Guidelines Committee
Sep 25, 2015·Expert Review of Anticancer Therapy·Rajasekharan Somasundaram, Meenhard Herlyn
Oct 17, 2015·Pigment Cell & Melanoma Research·Mitchell P LevesqueNiko Beerenwinkel
Nov 1, 2015·Journal of Hematology & Oncology·Katy K Tsai, Adil I Daud
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongKeith T Flaherty
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Dec 3, 2016·Cancer Discovery·Daniel Sanghoon ShinAntoni Ribas

❮ Previous
Next ❯

Citations

Nov 10, 2017·International Journal of Molecular Sciences·Stefano GuadagniCristina Pellegrini
May 16, 2018·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Ana B García-MartínRuth Lyck
Oct 5, 2019·International Journal of Cancer. Journal International Du Cancer·Mark P van OpijnenEllen H W Kapiteijn
Oct 14, 2020·The Journal of Investigative Dermatology·Florence PoizeauAlain Dupuy
Apr 12, 2021·Pharmacoepidemiology and Drug Safety·Su-Yeon YuSamantha Hollingworth
Aug 29, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marie-Luise HilbersJoanna Mangana

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01511913
NCT01668784
NCT01320085
NCT01436656
NCT01213472
NCT01597908
NCT01682083
NCT01307397
NCT01704287

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Current Opinion in Oncology
Simone M GoldingerPaul Nathan
Annals of Oncology : Official Journal of the European Society for Medical Oncology
M H Geukes FoppenW Boogerd
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
E PorneczyI Boncz
© 2022 Meta ULC. All rights reserved